Semler Scientific (SMLR) Stock Price, News & Analysis

Company Overview

Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. It also offers Insulin Insights, a software program that is used by a healthcare provider to optimize outpatient insulin dosing. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers. It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California.

Key Stats

• Today's Range: $47.61 to $53.27
• 50-Day Range: $46.98 to $74.73
• 52-Week Range: $20.88 to $81.56
• Volume: 282,980 shs
• Average Volume: 419,604 shs
• Market Capitalization: $442.55 million
• P/E Ratio: 9.72
• Dividend Yield: N/A
• Price Target: $71.00
• Consensus Rating: Buy

Semler Scientific Stock Analysis - MarketRank™

Semler Scientific scored higher than 61% of companies evaluated by MarketBeat, and ranked 450th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Semler Scientific has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Semler Scientific has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Semler Scientific is 9.72, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 23.70.

Price to Earnings Ratio vs. Sector

The P/E ratio of Semler Scientific is 9.72, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.81.

Price to Book Value per Share Ratio

Semler Scientific has a P/B Ratio of 4.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

23.96% of the float of Semler Scientific has been sold short.

Short Interest Ratio / Days to Cover

Semler Scientific has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Semler Scientific has recently increased by 51.69%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Semler Scientific does not currently pay a dividend.

Dividend Growth

Semler Scientific does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

23.96% of the float of Semler Scientific has been sold short.

Short Interest Ratio / Days to Cover

Semler Scientific has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Semler Scientific has recently increased by 51.69%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.65

News Sentiment

Semler Scientific has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Semler Scientific this week, compared to 3 articles on an average week.

Search Interest

8 people have searched for SMLR on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Semler Scientific to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Semler Scientific insiders have not sold or bought any company stock.

Percentage Held by Insiders

30.20% of the stock of Semler Scientific is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

49.37% of the stock of Semler Scientific is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SMLR Stock Analysis - Frequently Asked Questions

How have SMLR shares performed this year?

Semler Scientific's stock was trading at $54.00 on January 1st, 2025. Since then, SMLR shares have decreased by 11.6% and is now trading at $47.74.
View the best growth stocks for 2025 here.

How were Semler Scientific's earnings last quarter?

Semler Scientific, Inc. (NASDAQ:SMLR) announced its quarterly earnings data on Tuesday, February, 18th. The company reported $3.41 earnings per share for the quarter, topping analysts' consensus estimates of $0.20 by $3.21. The firm had revenue of $12.41 million for the quarter. Semler Scientific had a net margin of 72.65% and a trailing twelve-month return on equity of 50.77%.

Who are Semler Scientific's major shareholders?

Semler Scientific's top institutional investors include Capital International Investors (6.16%), Susquehanna Advisors Group Inc. (5.38%), Vanguard Group Inc. (3.30%) and Driehaus Capital Management LLC (2.02%).
View institutional ownership trends.

How do I buy shares of Semler Scientific?

Shares of SMLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Semler Scientific own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Semler Scientific investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), Arista Networks (ANET) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 2/18/2025
• Today: 2/23/2025
• Next Earnings (Estimated): 5/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Electromedical equipment
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:SMLR
• CUSIP: N/A
• CIK: 1554859
• Web: www.semlerscientific.com
• Phone: 877-774-4211
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $71.00
• High Stock Price Target: $71.00
• Low Stock Price Target: $71.00
• Potential Upside/Downside: +48.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $4.91
• Trailing P/E Ratio: 9.72
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $20.58 million
• Net Margins: 72.65%
• Pretax Margin: 30.75%
• Return on Equity: 50.77%
• Return on Assets: 47.04%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.14
• Quick Ratio: 3.09

Sales & Book Value

• Annual Sales: $56.29 million
• Price / Sales: 7.86
• Cash Flow: $2.82 per share
• Price / Cash Flow: 16.95
• Book Value: $10.45 per share
• Price / Book: 4.57

Miscellaneous

• Outstanding Shares: 9,270,000
• Free Float: 6,468,000
• Market Cap: $442.55 million
• Optionable: Not Optionable
• Beta: 1.17